> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Vaccine Ready for EUA Submission
- URL: https://www.fdaweb.com/astrazeneca-vaccine-ready-for-eua-submission/
- Published: 2020-11-23T12:00:00.000Z
- Updated: 2026-09-14T16:37:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148145

AstraZeneca says it is preparing an emergency use authorization request for its investigational vaccine AZD1222 after an interim analysis showed that the vaccine was highly effective in preventing Covid-19 and no hospitalizations or severe disease cases were reported in participants receiving the vaccine. There were a total of 131 Covid-19 cases in the interim analysis.

“One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart,” the company says. “The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. All results were statistically significant (p<=0.0001). More data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading and establishing the duration of protection.”

AstraZenca also reports that no serious safety events related to the vaccine have been confirmed.